Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Trial Profile

An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2019

At a glance

  • Drugs Nivolumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CheckMate057
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Jul 2019 Results assesasing pharmacological cost of first- and second-line treatments with pembrolizumab, nivolumab and atezolizumab using 6 phase III trials (KEYNOTE-024, -010, CheckMate-026, 017, 057 and OAK) published in the Anticancer Research
    • 22 May 2019 Results of Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients using data from 2 predominantly Chinese and 5 global studies, published in the Journal of Clinical Pharmacology
    • 15 May 2019 Results of PPK analysis using data from multiple clinical studies in patients with AdjMEL, MEL, NSCLC, and other tumor types (CA209-001, CA209-003, CA209-005, CA209-017, CA209-057, CA209-037, CA209-066, CA209-238, CA209-063 and CA209-051) published in the Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top